Posted inBiotechnology
Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials
Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to…








